IL2 and cancer: The efficacy of this approach was confirmed both in vitro and in vivo: a consistent level of cancer cell killing and tumor regression was detected in all models, and it was also accompanied by the release of IFN-gamma and IL-2 from MET-targeted CAR-T-cells, confirming that cancer cell death was immune-mediated.